BLAST - MT103-203

A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST)

Participating sites in Europe

application/pdf Participating Sites in Austria (55KB)
MT103-203
application/pdf Participating Sites in Belgium (55KB)
MT103-203
application/pdf Participating Sites in the Czech Republic (68KB)
MT103-203
application/pdf Participating Sites in France (95KB)
MT103-203
application/pdf Participating Sites in Germany (100KB)
MT103-203
application/pdf Participating Sites in Italy (67KB)
MT103-203
application/pdf Participating Sites in the Netherlands (50KB)
MT103-203
application/pdf Participating Sites in Poland (90KB)
MT103-203
application/pdf Participating Sites in Romania (102KB)
MT103-203
application/pdf Participating Sites in Russia (49KB)
MT103-203
application/pdf Participating Sites in Spain (61KB)
MT103-203
application/pdf Participating Sites in the United Kingdom (73KB)
MT103-203